Importer of Controlled Substances Notice of Application, 55583 [E9-25862]
Download as PDF
55583
Federal Register / Vol. 74, No. 207 / Wednesday, October 28, 2009 / Notices
In light of these circumstances, the
Commission has determined as follows:
(a) The public may submit comments on
remedy, the public interest, and
bonding until November 2, 2009. (b)
The parties and the public may reply to
any submissions on remedy, the public
interest, and bonding until November 9,
2009. (c) The parties’ schedule for
briefing on any issues related to
violation is unaffected by this extension.
This action is taken under the
authority of section 337 of the Tariff Act
of 1930, as amended (19 U.S.C. 1337),
and under sections 210.50 of the
Commission’s Rules of Practice and
Procedure (19 CFR 210.50).
Issued: October 23, 2009.
By order of the Commission.
Marilyn R. Abbott,
Secretary to the Commission.
[FR Doc. E9–26019 Filed 10–27–09; 8:45 am]
Commerce on or before November 17,
2009.)
6. Inv. Nos. 701–TA–473 and 731–
TA–1173 (Preliminary) (Certain Sodium
and Potassium Phosphate Salts from
China)—briefing and vote. (The
Commission is currently scheduled to
transmit its determinations to the
Secretary of Commerce on or before
November 9, 2009; Commissioners’
opinions are currently scheduled to be
transmitted to the Secretary of
Commerce on or before November 17,
2009.)
7. Outstanding action jackets: none.
In accordance with Commission
policy, subject matter listed above, not
disposed of at the scheduled meeting,
may be carried over to the agenda of the
following meeting.
BILLING CODE 7020–02–P
By order of the Commission.
Issued: October 26, 2009.
William R. Bishop,
Hearings and Meetings Coordinator.
[FR Doc. E9–26104 Filed 10–26–09; 4:15 pm]
INTERNATIONAL TRADE
COMMISSION
BILLING CODE 7020–02–P
[USITC SE–09–029]
DEPARTMENT OF JUSTICE
erowe on DSK5CLS3C1PROD with NOTICES
Government in the Sunshine Act
Meeting Notice
Drug Enforcement Administration
AGENCY HOLDING THE MEETING: United
States International Trade Commission.
TIME AND DATE: November 6, 2009 at 11
a.m.
PLACE: Room 101, 500 E Street, SW.,
Washington, DC 20436, Telephone:
(202) 205–2000.
STATUS: Open to the public.
MATTERS TO BE CONSIDERED:
1. Agenda for future meetings: none.
2. Minutes.
3. Ratification List.
4. Inv. Nos. 701–TA–470–471 and
731–TA–1169–1170 (Preliminary)
(Certain Coated Paper Suitable for HighQuality Print Graphics Using Sheet-Fed
Presses from China and Indonesia)—
briefing and vote. (The Commission is
currently scheduled to transmit its
determinations to the Secretary of
Commerce on or before November 9,
2009; Commissioners’ opinions are
currently scheduled to be transmitted to
the Secretary of Commerce on or before
November 17, 2009.)
5. Inv. Nos. 701–TA–472 and 731–
TA–1171–1172 (Preliminary) (Certain
Standard Steel Fasteners from China
and Taiwan)—briefing and vote. (The
Commission is currently scheduled to
transmit its determinations to the
Secretary of Commerce on or before
November 9, 2009; Commissioners’
opinions are currently scheduled to be
transmitted to the Secretary of
VerDate Nov<24>2008
15:34 Oct 27, 2009
Jkt 220001
Importer of Controlled Substances
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this Section to a
bulk manufacturer of a controlled
substance in schedule I or II, and prior
to issuing a regulation under 21 U.S.C.
952(a)(2) authorizing the importation of
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with Title 21
Code of Federal Regulations (CFR),
1301.34(a), this is notice that on August
27, 2009, Formulation Technologies
LLC., 11400 Burnet Road, Suite 4010,
Austin, Texas 78758, made application
by renewal to the Drug Enforcement
Administration (DEA) to be registered as
an importer of Fentanyl (9801), a basic
class of controlled substance listed in
schedule II.
The company plans to import the
listed controlled substance for analytical
characterization, secondary packaging,
and for distribution to clinical trial sites.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic class of controlled substance
may file comments or objections to the
issuance of the proposed registration
and may, at the same time, file a written
PO 00000
Frm 00048
Fmt 4703
Sfmt 4703
request for a hearing on such
application pursuant to 21 CFR 1301.43
and in such form as prescribed by 21
CFR 1316.47.
Any such comments or objections
being sent via regular mail should be
addressed, in quintuplicate, to the Drug
Enforcement Administration, Office of
Diversion Control, Federal Register
Representative (ODL), 8701 Morrissette
Drive, Springfield, Virginia 22152; and
must be filed no later than November
27, 2009.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745–46), all applicants for
registration to import a basic class of
any controlled substances in schedule I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: October 20, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–25862 Filed 10–27–09; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
This is notice that on July 9, 2009,
Cody Laboratories Inc., 601 Yellowstone
Avenue, Cody, Wyoming 82414–9321,
made application by renewal to the
Drug Enforcement Administration
(DEA) for registration as an importer of
the basic classes of controlled
substances listed in schedule II:
Drug
Raw Opium (9600) .......................
Concentrate of Poppy Straw
(9670).
Schedule
II
II
The company plans to import narcotic
raw materials for manufacturing and
further distribution to its customers.
The company is registered with DEA as
a manufacturer of several controlled
substances that are manufactured from
raw opium, poppy straw, and
concentrate of poppy straw.
E:\FR\FM\28OCN1.SGM
28OCN1
Agencies
[Federal Register Volume 74, Number 207 (Wednesday, October 28, 2009)]
[Notices]
[Page 55583]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-25862]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances Notice of Application
Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to
issuing a registration under this Section to a bulk manufacturer of a
controlled substance in schedule I or II, and prior to issuing a
regulation under 21 U.S.C. 952(a)(2) authorizing the importation of
such a substance, provide manufacturers holding registrations for the
bulk manufacture of the substance an opportunity for a hearing.
Therefore, in accordance with Title 21 Code of Federal Regulations
(CFR), 1301.34(a), this is notice that on August 27, 2009, Formulation
Technologies LLC., 11400 Burnet Road, Suite 4010, Austin, Texas 78758,
made application by renewal to the Drug Enforcement Administration
(DEA) to be registered as an importer of Fentanyl (9801), a basic class
of controlled substance listed in schedule II.
The company plans to import the listed controlled substance for
analytical characterization, secondary packaging, and for distribution
to clinical trial sites.
Any bulk manufacturer who is presently, or is applying to be,
registered with DEA to manufacture such basic class of controlled
substance may file comments or objections to the issuance of the
proposed registration and may, at the same time, file a written request
for a hearing on such application pursuant to 21 CFR 1301.43 and in
such form as prescribed by 21 CFR 1316.47.
Any such comments or objections being sent via regular mail should
be addressed, in quintuplicate, to the Drug Enforcement Administration,
Office of Diversion Control, Federal Register Representative (ODL),
8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed
no later than November 27, 2009.
This procedure is to be conducted simultaneously with, and
independent of, the procedures described in 21 CFR 1301.34(b), (c),
(d), (e), and (f). As noted in a previous notice published in the
Federal Register on September 23, 1975, (40 FR 43745-46), all
applicants for registration to import a basic class of any controlled
substances in schedule I or II are, and will continue to be, required
to demonstrate to the Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement Administration, that the
requirements for such registration pursuant to 21 U.S.C. 958(a); 21
U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: October 20, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E9-25862 Filed 10-27-09; 8:45 am]
BILLING CODE 4410-09-P